Floating Gastric Retentive Drug Delivery System

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a floating gastric retentive drug delivery system in the form of a closed hollow body made from a polymer matrix with a high drug content. Its density is less than that of gastric fluid, allowing it to float in the stomach and gradually release the active ingredient—such as metformin, levodopa, gabapentin, or pregabalin—over an extended period. The system is designed for high drug loading (45-85%), and its floating and release characteristics can be independently controlled by adjusting the structure and materials.

Use CasesContent extracted from patent full text and abstract with AI.

• Oral delivery of drugs that are optimally absorbed in the stomach or upper small intestine, such as metformin for diabetes or levodopa for Parkinson’s disease.
• Development of sustained release formulations for drugs with a narrow absorption window or quick upper GI transit.
• Improving bioavailability and therapeutic efficacy for medications requiring prolonged stomach residency.
• Compliance-friendly long-acting dosage forms, reducing dosing frequency for chronic therapies.
• Formulation of drugs sensitive to acidic degradation by protecting active ingredients until targeted release.

BenefitsContent extracted from patent full text and abstract with AI.

• Ensures prolonged gastric retention and controlled drug release in the stomach, aligning with the absorption window for certain drugs.
• Enables very high drug loading (up to 85%), making it suitable for medications requiring high doses.
• Offers independent control over floating capability and drug release rate, enhancing formulation flexibility.
• Can be manufactured using scalable processes such as extrusion, injection molding, or 3D-printing.
• Reduces variability in drug release kinetics when adjusting the dose, improving predictability and therapy management.
• Potentially boosts patient compliance by reducing the frequency of administration and optimizing drug exposure.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a floating gastric retentive drug delivery system, which has a density below 1 g/cm3, and which has the form of a closed hollow body, the hollow body being formed from a release sustaining matrix of a polymer component comprising an active ingredient dispersed therein, wherein the hollow body comprises the active ingredient in an amount in a range of ≥ 45 weight % to ≤ 85 weight %, based on a weight of 100 weight % of the hollow body.